← FDA Drug Approvals (Drugs@FDA)

CABOZANTINIB

ANDA · Abbreviated New Drug Application (Generic) · Sponsor: BIOCON PHARMA LIMITED · Approved 2026-03-17

Drug application

FDA Application #

ANDA220121

Application type

Abbreviated New Drug Application (Generic)

Brand name

CABOZANTINIB

Generic name

Cabozantinib

Active ingredients

CABOZANTINIB

Dosage form

TABLET

Route

—

Marketing status

None (Tentative Approval)

Sponsor

BIOCON PHARMA LIMITED

First approval

2026-03-17

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown